GlassScriptPhysician profile
Karisa K Son
NPI 1780064212
$9,927.19
in general payments reported to CMS, 2019-2025
25 companies · $3,115 in 2025
The $3,115 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $705 · 2022: $1,408 · 2023: $2,400 · 2024: $2,299 · 2025: $3,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,145 · Education: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,144.82 |
| Education | $669.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,840.05 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,811.35 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $964.12 | 2021-2025 | Blu-U, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $729.19 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $599.07 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $589.00 | 2021-2025 | Otezla, Enbrel, Otezla |
| Galderma Laboratories, L.P. | $491.25 | 2022-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $469.79 | 2022-2025 | Adbry, Anzupgo |
| Pfizer INC. | $442.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $392.85 | 2021-2025 | |
| Genzyme Corporation | $379.98 | 2021-2025 | |
| Ucb, INC. | $290.92 | 2024-2025 | Bimzelx |
| Incyte Corporation | $261.59 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $185.32 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.59 | 2022-2025 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $124.14 | 2021-2024 | Duobrii, Siliq, Arazlo |
| E.R. Squibb & Sons, L.L.C. | $32.47 | 2025 | Sotyktu |
| Biofrontera INC. | $26.72 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $25.92 | 2022 | |
| Almirall LLC | $20.83 | 2022 | |
| Botanix Sb INC | $19.96 | 2025 | Sofdra |
| Smith+Nephew, INC. | $14.74 | 2022 | |
| Dermavant Sciences, INC. | $13.36 | 2023 | Vtama |
| Glaxosmithkline, LLC. | $13.36 | 2021 | |
| Bioventus LLC | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karisa Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.